<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111666</url>
  </required_header>
  <id_info>
    <org_study_id>AL101-1</org_study_id>
    <nct_id>NCT04111666</nct_id>
  </id_info>
  <brief_title>A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101</brief_title>
  <official_title>A Phase 1 Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Bioavailability of IV and SC AL101</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alector Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alector Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A first in human phase 1 study in healthy volunteers to assess AL101 safety, tolerability,&#xD;
      bioavailability, pharmacokinetics, and pharmacodynamics&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human Phase 1 study designed to investigate the safety, tolerability, PK,&#xD;
      PD and Bioavailability of intravenously and sub-cutaneously administered AL101 in Healthy&#xD;
      Volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2019</start_date>
  <completion_date type="Anticipated">October 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety and tolerability of AL101 measured by number of subjects with adverse events and Dose Limiting Adverse Event (DLAEs)</measure>
    <time_frame>113 days</time_frame>
    <description>Incidence of adverse events and dose limiting Adverse Events during the DLAE observation period and/or study treatment periods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of AL101</measure>
    <time_frame>113 days</time_frame>
    <description>Serum and CSF concentration of AL101 at specified time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) for AL101</measure>
    <time_frame>113 days</time_frame>
    <description>Evaluate Cmax for serum and CSF concentration of AL101 at specified time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve concentration (AUC) for AL101</measure>
    <time_frame>113 days</time_frame>
    <description>Evaluate AUC for serum and CSF concentration of AL101 at specified time points</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AL101 IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to four single ascending doses of AL101 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution will be administered as a single infusion for each cohort in a ratio of 8 active and 3 placebo subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AL101 SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of AL101 administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AL101</intervention_name>
    <description>Active dose of AL101</description>
    <arm_group_label>AL101 IV</arm_group_label>
    <arm_group_label>AL101 SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline solution administered as a single infusion as palcebo.</description>
    <arm_group_label>Saline Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 18.0-35.0 kg/m2&#xD;
&#xD;
          -  45-120 kg, inclusive&#xD;
&#xD;
          -  At screening, females must be non-pregnant and non-lactating, or of nonchildbearing&#xD;
             potential (either surgically sterilized or physiologically incapable of becoming&#xD;
             pregnant, or at least 1-year postmenopausal (amenorrhoea duration of 12 consecutive&#xD;
             months); nonpregnancy will be confirmed for all females by a pregnancy test conducted&#xD;
             at screening, (each) admission, and at follow-up.&#xD;
&#xD;
          -  Female participants of child-bearing potential must agree to use adequate&#xD;
             contraception from screening until 90 days after the follow-up visit.&#xD;
&#xD;
          -  In good physical health on the basis of no clinically significant findings from&#xD;
             medical history, physical examination (PE), laboratory tests, 12 lead ECG, and vital&#xD;
             signs, as judged by the Investigator.&#xD;
&#xD;
          -  Willingness and able to comply with the study protocol, in the investigator's&#xD;
             judgement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric, human, or humanized antibodies or fusion proteins.&#xD;
&#xD;
          -  Positive drug or alcohol at screening and prior to first dose&#xD;
&#xD;
          -  History of alcohol abuse or substance abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Kusnir</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bioclinica Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Lead</last_name>
    <phone>650-422-7435</phone>
    <email>info@alector.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-841-0502</phone>
      <email>info@bioclinicaresearch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

